{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:57:40Z","timestamp":1785326260320,"version":"3.55.0"},"reference-count":44,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Cencora"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/13696998.2025.2584885","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:28:22Z","timestamp":1763558902000},"page":"2027-2038","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["A budget impact model for biosimilar denosumab for skeletal-related events and fractures in the United States oncology population"],"prefix":"10.1080","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3813-7921","authenticated-orcid":false,"given":"Jeanine","family":"Flanigan","sequence":"first","affiliation":[{"name":"Sandoz Inc","place":["Princeton, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Chaplin","sequence":"additional","affiliation":[{"name":"Cencora","place":["Conshohocken, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"van Stiphout","sequence":"additional","affiliation":[{"name":"Cencora","place":["Conshohocken, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0782-8816","authenticated-orcid":false,"given":"Marion","family":"Schauf","sequence":"additional","affiliation":[{"name":"Sandoz International GmbH","place":["Holzkirchen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4487-6595","authenticated-orcid":false,"given":"Mike","family":"Tindal","sequence":"additional","affiliation":[{"name":"Sandoz Inc","place":["Princeton, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2172-4262","authenticated-orcid":false,"given":"Andrea","family":"Gundlach","sequence":"additional","affiliation":[{"name":"Cencora","place":["Conshohocken, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8661-0560","authenticated-orcid":false,"given":"Edward","family":"Li","sequence":"additional","affiliation":[{"name":"Sandoz Inc","place":["Princeton, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary H.","family":"Lyman","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine","place":["Durham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.019"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0327"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-1887-3"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2014.890937"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2010.16.9.693"},{"key":"e_1_3_5_7_1","volume-title":"Secondary osteoporosis","author":"Ganesan K","year":"2025","unstructured":"Ganesan K, Jandu JS, Anastasopoulou C, et al. Secondary osteoporosis. Treasure Island, FL: StatPearls Publishing LLC; 2025."},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnab028"},{"key":"e_1_3_5_9_1","volume-title":"Prescribing information","author":"Prolia","year":"2020","unstructured":"Prolia. Prescribing information. Thousand Oaks, CA: Amgen Inc; 2020."},{"key":"e_1_3_5_10_1","volume-title":"Prescribing Information","author":"Xgeva","year":"2020","unstructured":"Xgeva. Prescribing Information. Thousand Oaks, CA: Amgen Inc; 2020."},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jbmr\/zjae016"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2024.08.007"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53554-7"},{"key":"e_1_3_5_14_1","unstructured":"Medicines AfA. The U.S. generic & biosimilar medicines savings report. 2024. https:\/\/accessiblemeds.org\/sites\/default\/files\/2024-09\/AAM-2024-Generic-Biosimilar-Medicines-Savings-Report.pdf"},{"key":"e_1_3_5_15_1","unstructured":"Food and Drug Administration. Overview for health care professionals. https:\/\/www.fda.gov\/drugs\/biosimilars\/overview-health-care-professionals."},{"key":"e_1_3_5_16_1","unstructured":"Biehn B. AmerisourceBergen U.S. Biosimilar report. https:\/\/www.amerisourcebergen.com\/-\/media\/assets\/cencora-biosimilars-usmarketlandscape-sep24.pdf"},{"key":"e_1_3_5_17_1","unstructured":"Administration FaD. Biosimilars. https:\/\/www.fda.gov\/drugs\/therapeutic-biologics-applications-bla\/biosimilars."},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1760284"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/op.20.00994"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.01963"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/op.22.00329"},{"key":"e_1_3_5_22_1","first-page":"6514","volume-title":"A successful model of biosimilar adoption in a community oncology practice","author":"Wilfong LS","year":"2021","unstructured":"Wilfong LS, Dave N, Garey JS, et al. A successful model of biosimilar adoption in a community oncology practice. J Clin Oncol. 2021;39(15 suppl):6514\u20136514."},{"key":"e_1_3_5_23_1","unstructured":"Cardinal Health. 2023 Biosimilars report. 2023. https:\/\/www.cardinalhealth.com\/content\/dam\/corp\/web\/documents\/Report\/cardinal-health-biosimilars-report-2023.pdf."},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1651122"},{"key":"e_1_3_5_25_1","unstructured":"Merative Micromedex\u00ae IBM Watson Health\u2122. RED BOOK. 2023. https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian."},{"key":"e_1_3_5_26_1","unstructured":"Centers for Medicare & Medicaid Services. Physician fee schedule look-up. 2023. https:\/\/www.cms.gov\/medicare\/physician-fee-schedule\/search."},{"key":"e_1_3_5_27_1","unstructured":"US Department of Health and Human Services. Part B biosimilar biological product payment and required modifiers. 2018. https:\/\/www.hhs.gov\/guidance\/document\/part-b-biosimilar-biological-product-payment-and-required-modifiers."},{"key":"e_1_3_5_28_1","unstructured":"Medicare. Medicare Costs 2023. Medicare Part B (medical insurance) costs. 2023. https:\/\/www.medicare.gov\/Pubs\/pdf\/11579-medicare-costs.pdf."},{"key":"e_1_3_5_29_1","unstructured":"Cubanski J Sroczynski N Neuman T. Medicare Part B drugs: cost implications for beneficiaries in traditional medicare and medicare advantage. 2022 https:\/\/www.kff.org\/medicare\/issue-brief\/medicare-part-b-drugs-cost-implications-for-beneficiaries-in-traditional-medicare-and-medicare-advantage\/."},{"key":"e_1_3_5_30_1","volume-title":"Prescribing information","author":"Zoledronic acid","year":"2020","unstructured":"Zoledronic acid. Prescribing information. Princeton, NJ: Dr. Reddy\u2019s Laboratories Ltd; 2020."},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809003"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)60995-3"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2022.100416"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02703-x"},{"key":"e_1_3_5_35_1","unstructured":"United States Census Bureau. Health Insurance Coverage in the United States: 2022. 2024. https:\/\/www.census.gov\/library\/publications\/2023\/demo\/p60-281.html."},{"key":"e_1_3_5_36_1","unstructured":"Siegel RL Giaquinto AN J A. CA: a cancer journal for clinicians. The flagship journal of American Cancer Society. 2024. https:\/\/acsjournals.onlinelibrary.wiley.com\/journal\/15424863."},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.Epi-16-0889"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.Epi-22-1038"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.7173"},{"key":"e_1_3_5_40_1","unstructured":"American Cancer Society. Multiple myeloma. 2024. https:\/\/www.cancer.org\/cancer\/types\/multiple-myeloma.html."},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4932"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.01160"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2214-109x(20)30215-1"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2021.09.014"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00774"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2025.2584885","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:47:34Z","timestamp":1766400454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2584885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/13696998.2025.2584885"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2025.2584885","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-09-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-29","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}